The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Ocul Immunol Inflamm. 2022 Aug;30(6):1533-1535. doi: 10.1080/09273948.2021.1896006. Epub 2021 Apr 7.
To report a unique case of Stevens-Johnson syndrome (SJS) with severe ocular complications induced by pembrolizumab, an immune checkpoint inhibitor.
A 64-year-old man with urothelial cancer presented with bilateral corneal epithelial defect and conjunctival pseudo-membrane formation with erythematous patches on the four extremities, abdomen, and back. He had urothelial cancer with multifocal lesions in the renal pelvis and left ureter, and para-aortic metastatic lymph nodes. Accordingly, pembrolizumab treatment was planned. Generalized skin eruption occurred 4 days after the first cycle of pembrolizumab treatment, and ocular symptoms occurred 2 weeks after the first cycle. The patient's symptoms improved after cessation of pembrolizumab treatment and administration of steroids systemically.
Immune checkpoint inhibitors, including pembrolizumab, have been developed recently and are widely used in the treatment of various cancers. However, it should be noted that the drugs may cause adverse events such as SJS with severe ocular complications.
报告一例由免疫检查点抑制剂帕博利珠单抗引起的史蒂文斯-约翰逊综合征（SJS）伴严重眼部并发症的罕见病例。
一名 64 岁男性，患有尿路上皮癌，表现为双侧角膜上皮缺损和结膜假膜形成，四肢、腹部和背部出现红斑。他患有肾盂和左输尿管多灶性病变以及腹主动脉转移性淋巴结的尿路上皮癌，因此计划进行帕博利珠单抗治疗。在第一周期帕博利珠单抗治疗后 4 天出现全身皮肤疹，在第一周期后 2 周出现眼部症状。在停止帕博利珠单抗治疗和全身应用类固醇后，患者症状改善。
免疫检查点抑制剂，包括帕博利珠单抗，近年来已被开发并广泛应用于各种癌症的治疗。然而，值得注意的是，这些药物可能会引起严重眼部并发症的 SJS 等不良反应。
